A 12-month Prospective Observational Study Assessing the Real-world Clinical Effectiveness, Safety and Health-economic Benefits of Toujeo® Initiation After Oral Antidiabetic Drug Failure in Insulin-naïve Patients With Type 2 Diabetes Mellitus

Primary Objective:

Assess effectiveness of insulin glargine (U300) in achieving glycemic goal measured by hemoglobin A1c (HbA1c).

Secondary Objectives:

• Assess effectiveness in achieving glycemic goal measured by HbA1c;
• Assess effectiveness on change in HbA1c, fasting plasma glucose (FPG) and self-monitored plasma glucose (SMPG) ;
• Assess requirement for intensification of therapy by additional antidiabetics.
• Assess incidence of hypoglycemia;
• Assess other safety endpoints: adverse events (AEs), serious adverse events (SAEs);
• Assess change in body weight.